Biotech News
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for